Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low- versus high-dose maintenance caffeine in preterm infants with respiratory distress
IRCT20160523028008N17Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of caffeine in respiratory distress syndrome (RDS) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Extubation failure, CPAP failure and 1 more. Started Nov 2021; status: completed.
02
Drugs
caffeine
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20160523028008N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160523028008N17.